Sarepta Therapeutics
Open
$15.79
Prev. Close
$15.78
High
$15.82
Low
$15.76
Market Snapshot
$1.66B
25.5
2.47
$1.9B
835
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 835 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, siRNA knockdown therapies, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS.
Recently from Cashu
Sarepta Therapeutics Pursues Growth via siRNA Development and Regulatory Approval Strategy
Sarepta Therapeutics (Ticker: SRPT) is positioning itself for future growth through the development of its small interfering RNA (siRNA) candidates, SRP-1001 and SRP-1003, which are showing promising…
Sarepta Therapeutics Pursues FDA Approval Amidst Investor Concerns Over Stock Decline
Sarepta Therapeutics Advances Regulatory Strategy Amid Investor Concerns Sarepta Therapeutics is currently focused on submitting supplemental new drug applications to the U.S. Food and Drug Administra…
Sarepta Navigates New FDA Leadership Changes Impacting Gene Therapy Regulations
Sarepta Therapeutics Enters a New Era of Regulatory Dynamics Amidst Leadership Changes at the FDA Sarepta Therapeutics, a leader in gene therapy innovations for genetic diseases, is positioned at a cr…
Regulatory Changes Could Boost Sarepta Therapeutics' Gene Therapy Innovations
Regulatory Shifts Signal Opportunities for Biopharmaceutical Innovation Sarepta Therapeutics stands at a potentially transformative juncture in the gene therapy landscape as the U.S. Food and Drug Adm…